{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:23:10Z","timestamp":1783059790032,"version":"3.54.6"},"reference-count":71,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012424","name":"University of California San Diego School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012424","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA023100"],"award-info":[{"award-number":["P30CA023100"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008637","name":"National Cancer Institute Center for Strategic Scientific Initiatives","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008637","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Methods"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.crmeth.2026.101422","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:40:27Z","timestamp":1778859627000},"page":"101422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improved expansion of peripheral blood and iPSC-derived natural killer cells for clinical applications"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-873X","authenticated-orcid":false,"given":"Jaya Lakshmi","family":"Thangaraj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2003-2494","authenticated-orcid":false,"given":"Dan S.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crmeth.2026.101422_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.crmeth.2026.101422_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082323","article-title":"The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy","volume":"15","author":"Yu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.crmeth.2026.101422_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.hemonc.2014.11.006","article-title":"Natural killer cells: In health and disease","volume":"8","author":"Mandal","year":"2015","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.crmeth.2026.101422_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1275076","article-title":"Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment","volume":"13","author":"Vu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.crmeth.2026.101422_bib5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.crmeth.2026.101422_bib6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.crmeth.2026.101422_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113139","article-title":"Natural Killer Cells in Immunotherapy: Are We Nearly There?","volume":"12","author":"Bachiller","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.crmeth.2026.101422_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859177","article-title":"Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy","volume":"13","author":"Tarannum","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib9","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtct.2022.06.025","article-title":"The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells","volume":"28","author":"Moscarelli","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.crmeth.2026.101422_bib10","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/stcltm\/szad087","article-title":"Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy","volume":"13","author":"Maia","year":"2024","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.crmeth.2026.101422_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.crmeth.2026.101422_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.crmeth.2026.101422_bib13","article-title":"GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1053\/j.seminoncol.2010.09.013","article-title":"Signaling through OX40 enhances antitumor immunity","volume":"37","author":"Jensen","year":"2010","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.crmeth.2026.101422_bib15","article-title":"Proliferation of Highly Cytotoxic Human Natural Killer Cells by OX40L Armed NK-92 With Secretory Neoleukin-2\/15 for Cancer Immunotherapy","volume":"11","author":"Guo","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.crmeth.2026.101422_bib16","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.4049\/jimmunol.173.6.3716","article-title":"Cross-Talk between Activated Human NK Cells and CD4+ T Cells via OX40-OX40 Ligand Interactions1","volume":"173","author":"Zingoni","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.692982","article-title":"Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors","volume":"9","author":"Mascarelli","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.crmeth.2026.101422_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.apsb.2019.08.010","article-title":"Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity","volume":"10","author":"Fu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.crmeth.2026.101422_bib19","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1002\/eji.200838250","article-title":"The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells","volume":"38","author":"Kober","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib20","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41419-024-06976-0","article-title":"Natural Killer cells at the frontline in the fight against cancer","volume":"15","author":"Co\u00ebnon","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.crmeth.2026.101422_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.968360","article-title":"4-1BB: A promising target for cancer immunotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.crmeth.2026.101422_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s12276-023-01136-4","article-title":"4-1BB immunotherapy: advances and hurdles","volume":"56","author":"Singh","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.crmeth.2026.101422_bib23","article-title":"Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042189","article-title":"Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles","volume":"22","author":"Ponath","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.crmeth.2026.101422_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4049\/jimmunol.2001004","article-title":"Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement","volume":"206","author":"Pekar","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2013-01-481705","article-title":"Induction of B7-H6, a ligand for the natural killer cell\u2013activating receptor NKp30, in inflammatory conditions","volume":"122","author":"Matta","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.crmeth.2026.101422_bib27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.omtm.2020.06.014","article-title":"Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways","volume":"18","author":"Yang","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.crmeth.2026.101422_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4049\/jimmunol.1701370","article-title":"HLA-F on HLA-Null 721.221 Cells Activates Primary NK Cells Expressing the Activating Killer Ig-like Receptor KIR3DS1","volume":"201","author":"Kiani","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12865-018-0272-x","article-title":"Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function","volume":"20","author":"Tremblay-McLean","year":"2019","journal-title":"BMC Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51287-6","article-title":"Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells","volume":"9","author":"Ojo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.crmeth.2026.101422_bib31","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1073\/pnas.86.20.8005","article-title":"Secretion and cell surface expression of IgG1 are impaired in human B lymphoblasts that lack HLA-A, -B, and -C antigens","volume":"86","author":"Burlingham","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.crmeth.2026.101422_bib32","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2007-07-101311","article-title":"NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities","volume":"111","author":"Diermayr","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.crmeth.2026.101422_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1189\/jlb.4AB1014-499R","article-title":"Functional analysis of NK cell subsets activated by 721.221 and K562 HLA-null cells","volume":"97","author":"Lisovsky","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.crmeth.2026.101422_bib34","article-title":"Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing","volume":"19","author":"Lee","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.crmeth.2026.101422_bib35","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/asheducation-2013.1.234","article-title":"Bringing natural killer cells to the clinic: ex vivo manipulation","volume":"2013","author":"Childs","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.crmeth.2026.101422_bib36","article-title":"X-ray-irradiated K562 feeder cells for expansion of functional CAR-T cells","volume":"33","author":"Bui","year":"2023","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.crmeth.2026.101422_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00879","article-title":"Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21","volume":"10","author":"Kweon","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-4939-3684-7_14","article-title":"Expansion of NK Cells Using Genetically Engineered K562 Feeder Cells","volume":"1441","author":"Phan","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.crmeth.2026.101422_bib39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00262-021-02982-9","article-title":"Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21","volume":"71","author":"Thangaraj","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.crmeth.2026.101422_bib40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cellimm.2014.04.011","article-title":"Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21","volume":"290","author":"Jiang","year":"2014","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732135","article-title":"Current Perspectives on \u201cOff-The-Shelf\u201d Allogeneic NK and CAR-NK Cell Therapies","volume":"12","author":"Heipertz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib42","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","article-title":"Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model","volume":"18","author":"Thangaraj","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00601","article-title":"Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy","volume":"6","author":"Chester","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105459","article-title":"B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies","volume":"110","author":"Lee","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.crmeth.2026.101422_bib45","article-title":"Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies","volume":"25","author":"Lee","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.crmeth.2026.101422_bib46","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1182\/bloodadvances.2020002084","article-title":"Human NK cells prime inflammatory DC precursors to induce Tc17 differentiation","volume":"4","author":"Clavijo-Salomon","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.crmeth.2026.101422_bib47","doi-asserted-by":"crossref","first-page":"29964","DOI":"10.1074\/jbc.M115.674010","article-title":"Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6","volume":"290","author":"Cao","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.crmeth.2026.101422_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/cancers13030577","article-title":"Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy","volume":"13","author":"Fern\u00e1ndez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.crmeth.2026.101422_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.seminhematol.2023.02.002","article-title":"The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors","volume":"60","author":"Piccinelli","year":"2023","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.crmeth.2026.101422_bib51","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.crmeth.2026.101422_bib52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.crmeth.2026.101422_bib53","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2017-05-785659","article-title":"Phase 1 clinical trial using mbIL21 ex vivo\u2013expanded donor-derived NK cells after haploidentical transplantation","volume":"130","author":"Ciurea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.crmeth.2026.101422_bib54","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omto.2022.12.006","article-title":"Expanded NK cells used for adoptive cell therapy maintain diverse clonality and contain long-lived memory-like NK cell populations","volume":"28","author":"Allan","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.crmeth.2026.101422_bib55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1515\/mr-2023-0031","article-title":"Current status and future perspective of natural killer cell therapy for cancer","volume":"3","author":"Zhao","year":"2023","journal-title":"Med. Rev."},{"key":"10.1016\/j.crmeth.2026.101422_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.802906","article-title":"Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing","volume":"13","author":"Gurney","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib57","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","article-title":"Disruption of TGF-\u03b2 signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells","volume":"31","author":"Thangaraj","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.crmeth.2026.101422_bib58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.crmeth.2026.101422_bib59","article-title":"Scalable process development of NK and CAR-NK expansion in a closed bioreactor","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.exphem.2016.10.003","article-title":"Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy","volume":"46","author":"Ayello","year":"2017","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.crmeth.2026.101422_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-76791-2","article-title":"Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts","volume":"14","author":"Jahan","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.crmeth.2026.101422_bib62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3389\/fbioe.2019.00194","article-title":"Mass Production of Highly Active NK Cells for Cancer Immunotherapy in a GMP Conform Perfusion Bioreactor","volume":"7","author":"Br\u00f6ker","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.crmeth.2026.101422_bib63","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13100-018-0139-y","article-title":"High-performance gene expression and knockout tools using sleeping beauty transposon system","volume":"9","author":"Hu","year":"2018","journal-title":"Mob. DNA"},{"key":"10.1016\/j.crmeth.2026.101422_bib64","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/CJI.0b013e3181ad762b","article-title":"Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes","volume":"32","author":"Nakazawa","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.crmeth.2026.101422_bib65","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jcyt.2023.08.003","article-title":"Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies","volume":"25","author":"P\u00e9rez del R\u00edo","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.crmeth.2026.101422_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-37779-6","article-title":"The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells","volume":"13","author":"Kaulfuss","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.crmeth.2026.101422_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.841107","article-title":"iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting","volume":"13","author":"Goldenson","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.crmeth.2026.101422_bib68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","article-title":"Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity","volume":"23","author":"Li","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.crmeth.2026.101422_bib69","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5966\/sctm.2012-0084","article-title":"Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy","volume":"2","author":"Knorr","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.crmeth.2026.101422_bib70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An improved method to produce clinical scale natural killer cells from human pluripotent stem cells","volume":"2048","author":"Zhu","year":"2019","journal-title":"Methods Mol Biol."},{"key":"10.1016\/j.crmeth.2026.101422_bib71","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell\u2013derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"}],"container-title":["Cell Reports Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667237526001220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667237526001220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:49:14Z","timestamp":1783057754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667237526001220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2667237526001220"],"URL":"https:\/\/doi.org\/10.1016\/j.crmeth.2026.101422","relation":{},"ISSN":["2667-2375"],"issn-type":[{"value":"2667-2375","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved expansion of peripheral blood and iPSC-derived natural killer cells for clinical applications","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crmeth.2026.101422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101422"}}